PubRank

Current Knowledge and Priorities for Future Research in Late Effects after Hematopoietic Stem Cell Transplantation (HCT) for Severe Combined Immunodeficiency Patients: A Consensus Statement from the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects after Pediatric HCT.

PubWeight™: 0.75‹?›

🔗 View Article (PMID 28068510)

Published in Biol Blood Marrow Transplant on January 06, 2017

Authors

Jennifer Heimall1, Jennifer Puck2, Rebecca Buckley3, Thomas A Fleisher4, Andrew R Gennery5, Benedicte Neven6, Mary Slatter5, Elie Haddad7, Luigi D Notarangelo8, K Scott Baker9, Andrew C Dietz10, Christine Duncan11, Michael A Pulsipher12, Mort J Cowan2

Author Affiliations

1: Division of Allergy and Immunology, Children's Hospital of Philadelphia, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
2: Department of Pediatrics, Allergy, Immunology, and Blood and Marrow Transplant Division, University of California San Francisco, San Francisco, California.
3: Departments of Pediatrics and Immunology, Duke University Medical Center, Durham, North Carolina.
4: Department of Laboratory Medicine, National Institutes of Health, Bethesda, Maryland.
5: Department of Paediatric Immunology, Newcastle upon Tyne, United Kingdom Institute of Cellular Medicine, Newcastle upon Tyne University, United Kingdom.
6: Department of Immunology, Bone Marrow Transplantation, Hopital Necker Enfants Malades, Paris, France.
7: Department of Pediatrics, Department of Microbiology, Infection and Immunology, University of Montreal, CHU Sainte-Justine, Montreal, Quebec, Canada.
8: Laboratory of Host Defenses, NIAID, National Institutes of Health, Bethesda, Maryland.
9: Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
10: Children's Center for Cancer and Blood Diseases, Children's Hospital Los Angeles, Los Angeles, California.
11: Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, Massachusetts.
12: Children's Center for Cancer and Blood Diseases, Children's Hospital Los Angeles, Los Angeles, California. Electronic address: mpulsipher@chla.usc.edu.

Associated clinical trials:

Autologous Gene Therapy for Artemis-Deficient SCID | NCT03538899

Articles by these authors ⇆

Bone mineral density in children with fanconi anemia after hematopoietic cell transplantation. Biol Blood Marrow Transplant (2015) 0.81

National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Subsequent Neoplasms Working Group Report. Biol Blood Marrow Transplant (2016) 0.79

Metabolic Syndrome and Cardiovascular Disease after Hematopoietic Cell Transplantation: Screening and Preventive Practice Recommendations from the CIBMTR and EBMT. Biol Blood Marrow Transplant (2016) 0.78

The Second Pediatric Blood and Marrow Transplant Consortium International Consensus Conference on Late Effects after Pediatric Hematopoietic Cell Transplantation: Defining the Unique Late Effects of Children Undergoing Hematopoietic Cell Transplantation for Immune Deficiencies, Inherited Marrow Failure Disorders, and Hemoglobinopathies. Biol Blood Marrow Transplant (2016) 0.77

Current Knowledge and Priorities for Future Research in Late Effects after Hematopoietic Cell Transplantation (HCT) for Inherited Bone Marrow Failure Syndromes (IBMFS): Consensus Statement From the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects after Pediatric HCT. Biol Blood Marrow Transplant (2017) 0.75

Avascular necrosis of bone after allogeneic hematopoietic cell transplantation in children and adolescents. Biol Blood Marrow Transplant (2014) 0.75

Endocrinopathies, Bone Health, and Insulin Resistance in Patients with Fanconi Anemia after Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant (2016) 0.75

Recommendations for Screening and Management of Late Effects in SCID Patients after Allogenic Hematopoietic Cell Transplantation (HCT): A Consensus Statement from the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects after Pediatric HCT. Biol Blood Marrow Transplant (2017) 0.75

Late Effects Screening Guidelines after Hematopoietic Cell Transplantation (HCT) for Inherited Bone Marrow Failure Syndromes (IBMFS): Consensus Statement From the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects after Pediatric HCT. Biol Blood Marrow Transplant (2017) 0.75

Survival and Late Effects after Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancy at Less Than Three Years of Age. Biol Blood Marrow Transplant (2017) 0.75

Current Results and Future Research Priorities in Late Effects after Hematopoietic Stem Cell Transplantation (HCT) for Children with Sickle Cell Disease and Thalassemia: a Consensus Statement From the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects after Pediatric HCT. Biol Blood Marrow Transplant (2017) 0.75

PROMIS measures can be used to assess symptoms and function in long-term hematopoietic cell transplantation survivors. Cancer (2017) 0.75